Moleculin Biotech ( (MBRX) ) just unveiled an update.
Moleculin Biotech has received IRB approval for its pivotal Phase 3 MIRACLE trial, evaluating Annamycin with Cytarabine for treating relapsed or refractory acute myeloid leukemia (AML). The trial aims to accelerate approval, with enrollment starting in early 2025. This adaptive study could bring a crucial treatment option to AML patients, supported by positive data and FDA alignment.
Learn more about MBRX stock on TipRanks’ Stock Analysis page.
Trending Articles
- ‘Steep Slide Is Likely to Continue,’ Says Analyst About Spirit Airlines Stock
- Shareholder Alert for Flux Power Holdings, Inc. (NASDAQ:FLUX)
- ValueAct’s $1B Stake in Meta Platforms is a Constructive Bet, Not an Activist Move
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
